Abstracts tagged "autoimmune diseases"

Abstract Number: 2278 • ACR Convergence 2023
Pregnancy in Connective Tissue Diseases: A 30 Year Follow-up Study of 465 Pregnancies from a Spanish Monocentric Registry
Cristiana Sieiro Santos¹, Paula Pérez García², Jose Ordas Martínez², Clara Moriano², Carolina Álvarez Castro² and Elvira Díez Álvarez², ¹Complejo Asistencial Universitario de León, León, Spain, ²CAULE, León, Spain
Background/Purpose: Pregnancy in patients with connective tissue diseases are known to be at high risk for the occurrence of adverse pregnancy outcomes. We aim toevaluate…
Abstract Number: 2513 • ACR Convergence 2023
Latent Class Analysis Identifies 2 Clinical Phenotypes of Immune Checkpoint Inhibitor-induced Inflammatory Arthritis
Laura Cappelli¹, Jamie Perin², Clifton Bingham³ and Ami Shah⁴, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Ellicott City, MD
Background/Purpose: : Immune checkpoint inhibitors (ICI) for cancer treatment can cause inflammatory arthritis (IA). ICI-IA is a heterogeneous entity affecting peripheral joints, tendons, and rarely…
Abstract Number: 0066 • ACR Convergence 2023
Mitochondrial Dysfunction and Fatigue in Sjögren’s Disease
Biji T Kurien¹, Rebecca Wood², Gavin Pharaoh³, Joshua Cavett¹, Valerie Lewis¹, Bhaskaran Shylesh¹, Lida radfar¹, Astrid Rasmussen¹, Christopher Lessard¹, A. Darise Farris¹, Kathy Sivils⁴, Kristi Koelsch¹, Holly Van Remmen¹ and R Hal Scofield⁵, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Edmond, OK, ³University of Washington, Seattle, WA, ⁴Janssen Research & Development, LLC, Edmond, OK, ⁵Oklahoma City Veterans Affairs Medical Center, Oklahoma City, OK
Background/Purpose: Sjögren's disease (SjD) is a chronic, autoimmune condition with diminished lacrimal and salivary gland secretion leading to keratoconjunctivitis sicca and xerostomia, respectively. In addition,…
Abstract Number: 0123 • ACR Convergence 2023
Improving Interpretation of Work Outcomes in Patients with Inflammatory Rheumatic Musculoskeletal Disease: General Population Reference Curves for Work Ability and At-work Productivity
Dafne Capelusnik¹, Wouter Smeets², Casper Webers³, Sofia Ramiro⁴, Elena Nikiphorou⁵, Roel Braekers², Laura Boekel⁶, Gertjan Wolbink⁷ and Annelies Boonen⁸, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Data science institute, Hasselt University, Hasselt, Belgium, ³Maastricht University, Maastricht, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵King's College London, London, United Kingdom, ⁶Amsterdam Rheumatology and Immunology Center, Location Reade, Department of Rheumatology, Amsterdam, Netherlands, ⁷Reade, Amsterdam, Netherlands, ⁸Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands
Background/Purpose: Data on self-reported presenteeism (limitations or reduced work productivity at work) in persons with inflammatory rheumatic and musculoskeletal diseases (iRMD) are challenging to interpret…
Abstract Number: 0253 • ACR Convergence 2023
Clinical Phenotypes in Patients with Isolated Anti-Sm/RNP Common Motif Antibody Positivity, Compared to Those with or Without Associated Anti-RNP Antibody Reactivity
Ruoning Ni¹ and Petar Lenert², ¹University of Iowa Hospitals and Clinics, Coralville, IA, ²University of Iowa Hospitals and Clinics, Iowa City, IA
Background/Purpose: Anti-ribonucleoprotein (RNP) and anti-Sm/RNP common motif antibodies play a critical role in diagnosing patients with systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD)…
Abstract Number: 0468 • ACR Convergence 2023
Patients with Autoimmune Skin Diseases Are at Increased Risk of Adverse Pregnancy Outcomes
Heejo Keum¹, Bonnie Bermas², Shivani Patel¹, Benjamin Chong¹ and Heidi Jacobe¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²UT Southwestern, Dallas, TX
Background/Purpose: Increased rates of adverse pregnancy outcomes (APOs) have been reported in association with rheumatologic diseases such as systemic lupus erythematosus (SLE), dermatomyositis (DM), and…
Abstract Number: 0609 • ACR Convergence 2023
Mortality After Autologous Hematopoietic Stem Cell Transplant for Autoimmune Disease: Do Scleroderma Patients Fare Worse?
Marina Birck¹, Autumn Neville¹, Jan Storek², Harry Atkins³, Marie Hudson⁴, Ines Colmegna⁵, Jessie R. Lavoie⁶, Jun Gao⁷ and Sasha Bernatsky¹, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²University of Calgary, Calgary, AB, Canada, ³Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁶Health Canada, Centre for Oncology, Radiopharmaceuticals and Research, Biologic and Radiopharmaceutical Drugs Directorate, Ottawa, ON, Canada, ⁷Health Canada, Centre for Regulatory Excellence, Statistics and Trials, Biologic and Radiopharmaceutical Drugs Directorate, Ottawa, ON, Canada
Background/Purpose: Autologous hematopoietic stem cell transplantation (HSCT) has benefitted some patients with autoimmune disease (AD) but is associated with toxicity and treatment-related mortality. Autologous HSCT…
Abstract Number: 0923 • ACR Convergence 2023
Identification of Lupus Nephritis Kidney Immune Populations via Hi-Resolution 20-Plex Immunohistochemistry Single-Cell Spatial Analyses
Caleb Marlin¹, Alessandra Ida Celia², Richard Furie³, Judith James¹, Andrea Fava⁴, Joel Guthridge¹, Avi Rosenberg⁵, Tayte Stephens¹, Christian Wright¹, Jeff Hodgin⁶, Peter Izmirly⁷, H Michael Belmont⁸, Jennifer Anolik⁹, Michelle Petri¹⁰, Jill Buyon¹¹, Diane L. Kamen¹², Chaim Putterman¹³, Accelerating Medicines Partnership in RA/SLE The¹, Chen-Yu Lee⁴ and Xiaoping Yang⁴, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²John Hopkins University of Medicine, Rome, Italy, ³Northwell Health, Manhasset, NY, ⁴Johns Hopkins University, Baltimore, MD, ⁵Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, ⁶University of Michigan, Ann Arbor, MI, ⁷New York University School of Medicine, New York, NY, ⁸NYU School of Medicine, New York, NY, ⁹University of Rochester Medical Center, Rochester, NY, ¹⁰Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ¹¹NYU Grossman School of Medicine, New York, NY, ¹²Medical University of South Carolina, Charleston, SC, ¹³Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Immunohistochemistry is the gold standard for antibody staining in microscopy. However, a lack of multiplexing limits its utility in the use of discovery. Here…
Abstract Number: 1064 • ACR Convergence 2023
Seroconversion Rates in Rituximab-Treated Rheumatic Patients Receiving COVID-19 Vaccination
Ryan Wilson¹, Junaid Awan², Mary Brady², Ciara Hunt², Fahd Adeeb³ and alexander fraser⁴, ¹University of Limerick, Buncrana, Ireland, ²University of Limerick, Limerick, Ireland, ³RCSI & UCD (Ireland) Malaysia Campus (RUMC), Malaysia, Malaysia, ⁴HSE, Limerick, Ireland
Background/Purpose: COVID-19 has increased the mortality rates among rheumatic patients, mainly those immunocompromised or with underlying comorbidities. During the COVID-19 vaccine development, patients on immunomodulatory…
Abstract Number: 1221 • ACR Convergence 2023
Familial Clustering of Dysbiotic Oral and Fecal Microbiomes in Juvenile Dermatomyositis (JDM)
Albert Chow¹, Sean Koester², Evan Pepper-Tunick³, Peggy Lee⁴, Mary Eckert⁵, Laurie Brenchley⁶, Pamela Gardner⁶, Naisi Li², adam Schiffenbauer⁷, Rita Volochayev⁷, Nastaran Bayat⁸, Jeffrey McLean⁹, Lisa Rider¹⁰, Susan Shenoi¹¹, Anne Stevens¹² and Neelendu Dey¹³, ¹Loma Linda University, Loma Linda, CA, ²Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA, ³Molecular Engineering & Sciences Institute, University of Washington, Seattle, WA, ⁴Department of Oral Medicine, School of Dentistry, University of Washington, Seattle, WA, ⁵Center for Clinical and Translational Research, Seattle Children’s Research Institute, Seattle, WA, ⁶Office of the Clinical Director, NIDCR, National Institutes of Health, Bethesda, MD, ⁷Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ⁸Social Scientific Systems, DLH Holdings Corp, Silver Spring, MD, ⁹Department of Periodontics, University of Washington, Seattle, WA, ¹⁰NIEHS, NIH, Bethesda, MD, ¹¹Seattle Childrens Hospital, Mercer Island, WA, ¹²Janssen, Hansville, WA, ¹³Department of Medicine, Division of Gastroenterology, University of Washington, Seattle, WA
Background/Purpose: JDM is a rare immune-mediated disease of childhood that is thought to result from genetic predisposition and environmental drivers, with documented links to microbial…
Abstract Number: 1494 • ACR Convergence 2023
The Effect of Belimumab on Steroid Use in Patients with SLE: Results from a Retrospective Observational Study of Real-World Data from a US Rheumatology Provider Network
Karen Worley¹, Scott Milligan² and Bernard Rubin³, ¹GlaxoSmithKline, US Value Evidence and Outcomes, Cincinnati, OH, ²Trio Health, Analytics, Louisville, CO, ³GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC
Background/Purpose: While oral CS (OCS) are the mainstay of SLE therapy, prolonged use is associated with organ damage and early mortality.1,2 Minimizing OCS use is…
Abstract Number: 1673 • ACR Convergence 2023
Immunomodulatory Treatment and Autoimmune Patient Responses to COVID-19 Booster Shots: Results from the Covid-19 VaccinE Response in Rheumatology Patients (COVER) Study
Amy S. Mudano¹, Gary Cutter², Ted R Mikuls³, Geoffrey Thiele⁴, Emily Holladay², Kevin Withrop⁵, Mark Law⁴, Bart Hamilton⁴, Monique Bastidas⁶, Michael Zikry⁶, Kelly Chun⁶, Michael George⁷ and Jeffrey Curtis², ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, ⁶Labcorp, Calabasas, CA, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Given an increased risk of COVID-19 in patients with autoimmune conditions, we must better understand the immunogenicity and safety of SARS-CoV-2 vaccines in people…
Abstract Number: 1871 • ACR Convergence 2023
Utility of Infrared Thermography in Patients with Digital Gangrene
Nidhish Chandra M, Puneet Kumar, Urmila Dhakad, Shweta Bhardwaj, Sanjay Pruthviraj Buddha, Parag Vijayvergia and Lily Singh, King George Medical University, Lucknow, India
Background/Purpose: Digital gangrene has been described as a complication of several Autoimmune Inflammatory Rheumatic Diseases(AIIRD). Due to multiple underlying mechanisms causing digital gangrene in AIIRD…
Abstract Number: 1971 • ACR Convergence 2023
Muscle Pathology in Patients with Primary Biliary Cholangitis
Jose Cesar Milisenda¹, Iago Pinal-Fernandez², Katherine Pak², Maria Casal-Dominguez³, Yaiza Duque-Jaimez⁴, Gloria Garrabou¹, Sandra Muñoz-Braceras⁵, Mariona Guitart-Manpel¹, Jose Jiram Torres-Ruiz⁵, Ester Tobias⁴, Maria Dolores Cano⁴, Iban Aldecoa⁴, Josep Maria Grau¹ and Andrew Mammen³, ¹Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain, ²National Institutes of Health, Bethesda, MD, ³NIH, Bethesda, MD, ⁴Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Muscle Disease Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease that primarily affects middle-aged women. It is characterized by elevated serum alkaline phosphatase levels,…
Abstract Number: 2289 • ACR Convergence 2023
Short and Long Term Outcomes of Patients with Pure Membranous Lupus Nephritis Compared to Patients with Proliferative Disease
Fadi Kharouf¹, Juan Pablo Diaz Martinez², Dafna Gladman³ and Zahi Touma⁴, ¹University Health Network and University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada
b>Background/Purpose: Patients with pure membranous lupus nephritis (LN) are known to have a different disease course than those with proliferative disease. The aim of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].